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KEY POINTS
 The presence of certain molecular, biological, and psychosocial factors at certain points in
the life span, has been linked to later development of schizophrenia.
 Environmental risk factors for schizophrenia include prenatal exposures, obstetric com-
plications (OCs), childhood trauma, urban birth, migrant status, and adolescent cannabis
use.
 Identified risk factors are neither necessary nor sufficient causal factors for schizophrenia.
The vast majority of people who are exposed to them do not develop schizophrenia and
a majority of individuals with schizophrenia may not have had the specific exposure in
question.
 These risk factors cannot be ignored because of their small effect and need to be consid-
ered in the context of schizophrenia as a lifelong brain disorder.INTRODUCTION
The presence of certain molecular, biologic, and psychosocial factors at certain points
in the life span, has been linked to later development of schizophrenia. These include
common and rare genetic variants; prenatal exposures, such as infection, stress, and
nutrition; OCs; childhood trauma; urban birth; migrant status; and adolescent
cannabis use. Some of these risk factors operate on an individual level and some
on a societal level but all need to be considered in the context of schizophrenia as
a lifelong brain disorder. Research interest in schizophrenia is shifting to ever-earlier
stages of the disease process, so the journey to discover the causes of schizophrenia
is leading back to late childhood/early adolescence as the important time period in the
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Historical findings show that OCs as a broad category of risk factor for schizophrenia
has a modest but consistently found association with schizophrenia. Odds ratios
(ORs) of 1.5 to 2.0 have been replicated in several population-based cohort studies
using prospective data.1 Within this broad category of complications there is good
evidence of an association between 10 specific complications and schizophrenia—
these are complications of pregnancy, such as bleeding, preeclampsia, diabetes,
and rhesus incompatibility; abnormal fetal growth and development measures, such
as low birth weight, congenital malformations, and small head circumference; and
complications of delivery, such as asphyxia, uterine atony, and emergency cesarean
section. The evidence supporting an association between these individual complica-
tions and schizophrenia comes from the largest studies with the most reliable epide-
miologic data that have explored the link between prenatal/neonatal life and the
development of schizophrenia in adulthood.
The past decade has seen few comparable studies conducted that have used
population-based, prospective data. The only study to do so and to also examine
a broad range of OCs was by Byrne and colleagues.2 This large, nested, case-
control study using Danish register–based data found an almost 2-0 fold increase in
the rate of schizophrenia among those who had experienced any one of the following
complications: maternal nonattendance at antenatal appointments, gestational age of
37 weeks or less, preeclampsia, threatened premature delivery, hemorrhage during
delivery, manual extraction of the baby, andmaternal sepsis of childbirth and the puer-
perium. The data was adjusted for the confounding effects of family psychiatric history
and socioeconomic and demographic factors. The evidence for the association
between OCs and schizophrenia coming from this large, well-controlled study with
good quality data is in keeping with previous findings—an association exists but it
is modest.
Several other cohort studies using population-based data have recently been con-
ducted but they have only addressed specific OCs,3,4 such as the association
between fetal growth measures and schizophrenia (in a cohort of Swedish male
conscripts); instead of, the association between prenatal exposure to maternal hyper-
tension/diuretic treatment and schizophrenia; and the association between prenatal
exposure to analgesics and schizophrenia (both in a Danish cohort using national
population-based register data).5,6 Finally, one study7 examined the association
between maternal-fetal blood incompatibility and schizophrenia in a large California-
based cohort. Evidence from these studies suggests the following:1. Birth weight is not associated with schizophrenia when gestational age is taken into
account.
2. Maternal hypertension and diuretic treatment during pregnancy are OCs of note—
experience of either one in the third trimester independently increases the odds of
the exposed offspring developing schizophrenia 2-fold and experience of both
increases the odds 4-fold.
3. Prenatal exposure to analgesics is an OC equally worthy of note with exposure
increasing the odds of schizophrenia 4-fold, after adjustment for the confounding
effects of parental history of schizophrenia, prenatal infection exposure, exposure
to other drugs in the prenatal period, other pregnancy complications, and parental
social status and parental age.
4. Maternal-fetal blood incompatibility leads to a 2-fold increase in the rate of schizo-
phrenia in adulthood among exposed offspring.
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example, evidence suggests that perinatal hypoxia may have lasting effects on dopa-
minergic function. The same data also suggest, however, a further indirect effect of
OCs such that birth insults alter the manner in which dopamine function is regulated
by stress in adulthood.9 Cannon and colleagues10 have recently found that neurotro-
phic factors, perhaps stimulated in response to fetal distress, may be important in the
origin of schizophrenia. In this nested case-control study, assays from cord and
maternal blood samples taken at delivery showed that, among schizophrenia patients,
birth hypoxia was associated with a 20% decrease in brain-derived neurotrophic
factor (BDNF) whereas among the matched healthy controls birth hypoxia was asso-
ciated with a 10% increase in BDNF. The deleterious effects of OCs, such as hypoxia
and hyperbilirubinaemia, on N-methyl-D-aspartate (NMDA) receptors have also been
proposed as a potential mechanism.11
Hypoxia itself has been proposed to mediate the effects of other OCs. Cannon and
colleagues12 found a linear relationship between the number of hypoxia causing OCs,
such as abnormal fetal heart rate, third-trimester heart rate, placental hemorrhaging,
and risk of schizophrenia, suggesting that any association between these specific
OCs and schizophrenia is accounted for by the effect of hypoxia on risk for schizo-
phrenia. These data also suggest that hypoxia interacts with genetic susceptibility
to further increase risk. The risk of schizophrenia increased with the number of
hypoxia-related OCs within families—given genetic vulnerability to schizophrenia,
those who were exposed to hypoxia were more likely to develop schizophrenia than
family members not exposed to hypoxia.CANNABIS USE
Over the past 5 years, robust epidemiologic studies with prospective data on cannabis
use have shown that cannabis confers an increase in risk for schizophrenia. Several
reviews and meta-analyses examining this association have been published since
2004 and all have concluded that the evidence supports cannabis as a component
cause of schizophrenia.13 The results of the meta-analyses varied from an overall
2-fold to a 2.9-fold increase in later schizophrenia outcomes in cannabis users.
Early-onset or adolescent-onset cannabis use confers an even higher risk of later
schizophrenia—approximately 4-fold.
The majority (90%) of adolescents who abuse cannabis do not develop schizo-
phrenia. The risk for psychotic illness attached to cannabis use seems influenced
by the amount used and the duration of use as well as the type or strength of
cannabis.14 Individual genetic susceptibility may also be important. Caspi and
colleagues,15 using data from the Dunedin Multidisciplinary Health and Development
Study, showed that individuals with the high-activity allele (val) of the COMT gene
were more likely to develop schizophrenia or schizophreniform disorder in adulthood
if they had used cannabis in adolescence, with the effect more marked in those who
had used cannabis earlier in adolescence, whereas this effect was not seen among
individuals who were homozygous for the low-activity (Met) allele. Individuals who
were heterozygous (Val/Met) were also found at increased risk, but the effect was
less marked. Both self-report and informant reports of psychotic symptoms yielded
a similar pattern of results,16 with findings that cannabis use is associated with
a greater frequency of hallucinogenic experiences in Val allele carriers who had
high psychosis liability at baseline. It is not yet known how cannabis exerts its
effect on risk of psychosis, but it seems likely to involve changes in dopamine
transmission.
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increase in relative risk on an individual level but has a much greater effect at
a population level given its widespread use in the general population. It has been
estimated that 8% to 15% of all schizophrenia can be attributed to cannabis
use.17,18PRENATAL INFECTION
Mednick and colleagues19 first reported an increased risk of schizophrenia among
individuals exposed prenatally to the 1957 influenza epidemic in Helsinki. Most subse-
quent studies examining this issue have found a positive association but there have
also been some negative findings (Brown20 provides an extensive review of this liter-
ature). One reason for the inconsistent results is likely to be the differing methodolo-
gies used across studies, with earlier studies using ecologic designs in which large
populations were deemed exposed if they were in utero at the time of an influenza
epidemic and later studies taking advantage of archived maternal serum to establish
individual exposure to the infection. Earlier studies pointed to the importance of expo-
sure to infection during the second trimester of fetal development, but the more robust
recent work places the window of vulnerability in the first trimester.21,22 A wide variety
of infections, such as influenza, herpes, polio, rubella, toxoplasmosis, and respiratory
infections, have been implicated. The effect sizes reported for the association
between prenatal exposure to infection and later schizophrenia have generally been
in the region of a 1.5-fold to 2-fold increase in risk.23,24 Studies using prenatal serum
samples, however, have found that those exposed prenatally to rubella had a 10-20-
fold increase in risk of adult schizophrenia25 and that those exposed during the first
trimester of gestation to influenza had a 7-fold increase in risk.22 There is some
evidence that prenatal exposure to infection may be interacting with another risk factor
for schizophrenia, such as genetic risk, to produce its effect.26 We found an additive
effect of having a positive family history such that, when coupled with prenatal expo-
sure to infection, the risk is significantly increased relative to either risk factor on its
own. There was an almost 5-fold increase in the odds of having schizophrenia for indi-
viduals with both psychosis liability and prenatal infection exposure compared with
individuals without either risk factor.
Despite much speculation, the mechanism by which prenatal infection increases the
risk of schizophrenia has not yet been elucidated. An indirect effect of infection on fetal
brain development seems the most plausible pathogenic mechanism. The wide range
of infections associated with schizophrenia during the prenatal period indicates that
some pathogenic mechanism common to many infections, such as the maternal
immune response to infection, may be in operation. Possible indirect mechanisms
include maternal IgG antibodies elicited by the infection or an infection-induced
excess of maternal cytokines, either of which may damage the developing fetus.27
A positive association between elevated maternal levels of the cytokine interleukin-8
during pregnancy and an increased risk of schizophrenia spectrum disorders in the
offspring has been found.22
The findings of immune dysregulation in schizophrenia28 and evidence of abnormal
expression of immune-related genes in postmortem schizophrenia studies29 support
the idea of the maternal immune response as the important mechanism. Animal
models of infection have provided evidence that the maternal immune response
affects fetal brain development in ways that are consistent with neuropathology
seen in schizophrenia. Abnormalities in the hippocampus and cortex as well as in
cerebellar white matter and evidence of altered behavior, such as deficits in social
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models of maternal infection.30 In addition, there is evidence that some of the behav-
ioral deficits are ameliorated by administration of antipsychotic medication30 and that
several other risk factors for schizophrenia, such as winter birth, urban birth, fetal
hypoxia, maternal stress, and maternal nutrition, elevate cytokine levels.30 This finding
suggests that perhaps maternal immune response may mediate the effects of other
environmental risk factors that have been assumed to have independent effects on
risk of schizophrenia.PRENATAL STRESS
There is a growing body of literature examining the causal relationship between
prenatal exposure to stress and the development of schizophrenia and other
psychotic disorders in adulthood. The prenatal stress/schizophrenia association has
been examined in several different ways. Death of spouse31,32 and experience of cata-
strophic events, such as war33 and nuclear explosion,34 have been found to increase
the risk of schizophrenia among those exposed. van Os and Selten33 found an
increased relative risk (RR) of schizophrenia (RR 1.28) among those in the Netherlands
who were in their first or second trimester during the Nazi invasion in May 1940, and
Malaspina and colleagues35 found that those in their secondmonth of gestation during
the 1967 Arab-Israel War (Six-Day War) also had an increased risk of schizophrenia.
Imamura and colleagues34 found that those exposed in their second or third trimester
to the nuclear explosion in Nagasaki were at increased risk of schizophrenia. Myhrman
and colleagues36 showed that the risk of schizophrenia among unwanted children was
raised compared with wanted or mistimed children, even after adjustment for con-
founding by sociodemographic, pregnancy, and perinatal variables (odds ratio [OR]
2.4). This study examined self-ratings of a woman’s desire to be pregnant. The ratings
were gathered prospectively beginning in the sixth or seventh month of gestation. The
association was present after accounting for both maternal depression and measures
of fetal well-being at the time of the birth. Khashan and colleagues32 found that death
or serious illness of a relative during the first trimester was associated with an
increased risk of developing schizophrenia, even when several potential confounders
were controlled for. This partially replicates the classic finding of Huttunen and Niska-
nen.31 This study showed that those whose fathers had died during their fetal period
were at an increased risk of schizophrenia compared with those whose fathers had
died during early childhood. This epidemiological evidence has been supported by
recent animal work linking prenatal stress and impaired behavioral adjustment/
emotional reactivity in the offspring.
As in the infection studies, the diversity of stress exposures associated with schizo-
phrenia raises the possibility of a single pathophysiologic mechanism underlying the
association. The common denominator could be the stress response and the resulting
glucocorticoid hormones known to be precipitated by psychological stressors.37
Animal models of prenatal stress have informed our understanding of the mechanisms
at play. For example, it has been shown in humans that the greatest sensitivity of the
developing fetus to stress is likely to be during late first or second trimester of preg-
nancy,19 when, based on animal evidence, glucocorticoid receptor expression is
commencing in the developing fetal brain. The precise timing of glucocorticoid
receptor expression in the developing human brain, however, is currently unknown.
Collectively, the findings from animal studies suggest that exposure of the developing
brain to stress-induced glucocorticoid hormones generates a syndrome that recreates
some aspects of the schizophrenia phenotype.38
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phrenia association have not had information on maternal adverse responses to
stress, such as substance abuse, which may mediate the association. And there is
evidence that the schizophrenia–risk-increasing effect of maternal stress during preg-
nancy may overlap with the risk-inducing effects of other environmental factors, thus
making it hard to delineate independent effects of some of the risk factors discussed in
this article. For example, psychological stress and neuroendocrine markers of stress
can affect immune function and, therefore, susceptibility to infection39; maternal
stress during pregnancy has been shown to increase the risk of fetal hypoxia,40 which,
in turn, has been show to increase the risk of schizophrenia; and stress has been
shown to alter people’s eating behavior, steering them toward sweet and fatty foods41
and possibly leading to maternal micronutritional deficiencies during pregnancy.
CHILDHOOD TRAUMA
Recent evidence has shown that childhood trauma is a risk factor for the development
of schizophrenia42–44 and psychotic symptoms.45 Although several previous studies
have suffered from methodological limitations, such as small, highly selected samples
and nonstandardized measures of trauma, a recent study has sought to overcome
these problems. Heins and colleagues46 examined exposure to childhood trauma
among nonaffective psychosis patients from geographically representative clinics in
Holland and Belgium. Siblings of patients and healthy control were recruited as
comparison groups. The use of a sibling comparison group helped to control for
any unmeasured familial confounding in the associations examined. Heins and
colleagues showed that those with childhood trauma had 4 times the odds of devel-
oping a psychotic disorder and that there was a dose-response effect present such
that patients had more trauma exposure than their siblings, who, in turn, had more
trauma exposure than the healthy comparison group. In addition, childhood abuse,
but not neglect, was significantly associated with the positive symptoms of psychosis;
there was no such association with negative symptoms. This finding indicates that
there may be symptom-specific and exposure-specific mechanisms at play.
Our work has shown significant associations between psychotic symptoms in early
adolescence and reports of child physical abuse, exposure to domestic violence, and
involvement in bullying45 and that cannabis use and childhood trauma both indepen-
dently increased the risk for psychotic symptoms in adolescence.44 Both cannabis
use and childhood trauma, however, additively interacted to increase the likelihood
of psychotic symptoms in adolescence to a much greater extent than either risk factor
independently. This indication of environmental factors working together to produce
a synergistic effect on risk has been found in other studies. Cougnard and
colleagues47 examined data from 2 large European population cohort studies (1 adult
cohort and 1 cohort aged 14–24 years) and calculated the additive interaction
between 3 environmental risk factors for psychosis (cannabis use, childhood trauma,
and urbanicity) and baseline psychotic experiences in predicting persistence of
psychotic experiences. The authors concluded that level of environmental risk
combines synergistically with subclinical psychotic symptoms to cause abnormal
persistence of these symptoms.
PRENATAL NUTRITION
Evidence for the involvement of prenatal nutrition in the pathway to schizophrenia in
some individuals has come from several sources. First, ecological evidence comes
from the study of populations exposed to famine. Individuals exposed to the Dutch
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(1958–1961) had a greater risk of developing schizophrenia compared with those
not exposed to these famines. Although data of this ecological nature are open to
methodologic criticisms, data from studies on micronutritional deficiencies and risk
of schizophrenia come from more robust studies. There is evidence that deficiencies
of folate, vitamin D, iron, and protein during the prenatal period all independently
increase the risk of schizophrenia. Homocysteine levels are linked to folate in the
metabolic cycle48; and elevated maternal homocysteine levels in the third trimester
have been shown to be associated with a 2-fold increase in risk of schizophrenia in
the offspring. McGrath and colleagues49–51 have shown that vitamin D supplementa-
tion in males in Finland reduced the incidence among these individuals and that both
low and high concentrations of neonatal vitamin D are associated with an increase risk
of schizophrenia; and a large Danish showed that those exposed to prenatal iron defi-
ciency had a 4-fold increase in risk of schizophrenia. There has been some evidence to
suggest that polyunsaturated fatty acids deficiency during gestation increases the risk
of schizophrenia but this evidence has largely been indirect and from animal studies.
McGrath and colleagues have also shown that vitamin D–deficient rats have features
characteristic of schizophrenia, such as enlarged ventricles, a thinner neocortex, and
altered behavior in adulthood, such as hyperlocomotion and impaired latent inhibi-
tion.52 There is also animal evidence suggesting that exposure to suboptimal levels
of protein in utero leads to abnormalities in brain development that are similar to those
seen in schizophrenia patients, such as a reduced number of hippocampal cells, and
affects behavior in ways consistent with the schizophrenia phenotype, such as
reduced prepulse inhibition and adverse effects on learning and memory.53
Several biological pathways, both direct and indirect, possibly mediate the associ-
ation between prenatal nutritional deficiency and later schizophrenia. Direct effects
are possible because many micronutrients are important components of molecules
in neurodevelopment and indirect effects are possible because it is plausible that
nutritional deficiencies could result in de novo mutations in genes critical for brain
development.54 Table 1 outlines some of the recent studies examining environmental
risk factors for schizophrenia.EPILEPSY AS A RISK FACTOR FOR SCHIZOPHRENIA
The nature of the relationship between psychosis and epilepsy has been of great
interest to psychiatrists for more than a century.62–65 The majority of studies66–68
have found a higher prevalence of psychosis in patients with epilepsy compared
with the general population, but this finding varies greatly, with reported rates varying
from 0.48%69 to 35.7%.70 A seminal Icelandic population study surveyed a complete
population of all individuals with epilepsy in Iceland and reported a rate of psychosis
of 7.2%.71
In a systematic review andmeta-analysis that we conducted, the pooled prevalence
rate for schizophrenia in epilepsy patients was 1.3% (95% CI, 0.7–1.7) (Fig. 1). This
percentage was found after pooling a total of 17 articles. A large Danish population–
based study found that people with a history of epilepsy have nearly 2.5 times the
risk of developing schizophrenia and nearly 3 times the risk of developing a schizo-
phrenia-like psychosis compared with the general population.72 It was also found
that both a family history of psychosis and a family history of epilepsy increase the
risk of schizophrenia.
In a population-based family study examining shared susceptibility to epilepsy and
psychosis, we found that individuals with epilepsy had a 5.5-fold increase in the odds
Table 1
A selection of recent studies examining the association between environmental risk factors and schizophrenia
Risk Factor Author Description
1. Obstetric complications
Fetal growth Gunnell et al,3 2003
Gunnell et al,4 2005
Swedish cohort study: no association when gestational age is taken into account
Medication Sørensen et al,6 2004
Sørensen et al,5 2003
Danish cohort study: OR 4.7 (95% CI, 1.9–12.0) for prenatal exposure to analgesics in the
second trimester
Danish cohort study: OR 4.0 (95% CI, 1.4–11.4) for prenatal exposure to both hypertension
and diuretic treatment in the third trimester
Rhesus incompatibility Hollister et al,55 1996
Insel et al,7 2005
Case-control study: rate of 2.1% vs 0.8% for Rh incompatible vs Rh compatible
Californian cohort study: RR 2.2 (95% CI, 1.1–4.4) for male offspring where there was
maternal-fetal blood incompatibility
2. Cannabis use Henquet et al,17 2005
Moore et al,18 2007
Meta-analysis of epidemiological studieswith prospective data: pooledOR2.1 (95%CI, 1.7–2.5)
Meta-analysis of epidemiological studieswith prospective data: pooledOR1.4 (95%CI, 1.2–1.6)
3. Prenatal infection
Influenza
Taxoplasmosis
Herpes
Rubella
Respiratory infection
Genital-reproductive
infection
Brown et al,22 2004
Brown et al,56 2005
Brown et al,57 2006
Brown et al,21 2000
Brown et al,58 2000
Babulas et al,59 2006
Serologic nested case-control study: OR 3.0 (95% CI, 0.9–10.1) for the first half of pregnancy
Serologic nested case-control study: OR 2.6 (95% CI, 1.0–6.8) for high IgG antibody titre
Serologic nested case-control study: no association found
Birth cohort study: RR 5.2 (95% CI, 1.9–14.3) for nonaffective psychosis
Birth cohort study: RR 2.1 (95% CI, 1.0–4.3) for secondnd trimester
Birth cohort study: RR 5.0 (95% CI, 2.0–12.6) for periconceptional period
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4. Prenatal stress
Death/illness of relative Huttunen and
Niskanen,31 1978
Khashan et al,32 2008
Finnish cohort study: significant increase in risk for prenatal compared with postnatal death
of spouse
Danish birth cohort: RR 1.67 (95% CI, 1.0–2.7) for death of relative during first trimester
War van Os and Selten, 199833
Malaspina et al,35 2008
Dutch birth cohort: RR 1.1 (95% CI, 1.0–1.2) for exposure in second trimester
Jerusalem birth cohort: hazard ratio 2.3 (95% CI, 1.1–4.7) for first-trimester exposure
Unwanted pregnancy Myhrman et al,36 1996 Finnish birth cohort: OR 2.5 (95% CI, 1.5–4.2) for children of unwanted pregnancies
5. Childhood trauma Kelleher et al,45 2008
Harley et al,44 2010
Heins et al,46 2011
Irish cohort study: OR 5.9 (95% CI, 1.2–27.9) for childhood physical abuse and risk of psychotic
symptoms in adolescence
Irish cohort study: OR 6.1 (95% CI, 1.6–23.1) for childhood trauma and psychotic symptoms
Case-control study: OR 4.5 (95% CI, 2.7–7.3) for childhood trauma and nonaffective psychotic
disorder
6. Prenatal nutrition
Iron deficiency Insel et al,51 2008
Sørensen et al,60 2010
Californian cohort study: RR 3.7 (95% CI, 1.4–9.8) for maternal mean hemoglobin of
10 g/dL or less
Danish cohort study: OR 1.6 (95% CI, 1.2–2.2) for maternal anemia during pregnancy
Homocysteine Brown et al,48 2007 Nested case-control study: OR 2.3 (95% CI, 1.1–4.8) for elevated third-trimester
homocysteine levels
Vitamin D McGrath et al,61 2003 Nested case-control study: OR 0.7 (95% CI, 0.5–1.0) for African American subgroup
P
re
d
ictin
g
R
isk
a
n
d
th
e
E
m
e
rg
e
n
ce
o
f
Sch
izo
p
h
re
n
ia
5
9
3
Overall  (I-squared = 95.3%, P = .000)
Study
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ID
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14
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1.28 (0.79, 1.76)
0.70 (0.50, 0.90)
8.80 (5.08, 12.52)
1.90 (-1.82, 5.62)
0.50 (-0.48, 1.48)
3.20 (1.63, 4.77)
1.20 (-0.17, 2.57)
1.30 (-0.46, 3.06)
3.80 (-1.30, 8.90)
ES (95% CI)
1.10 (-1.06, 3.26)
5.30 (-0.58, 11.18)
4.10 (-0.41, 8.61)
0.80 (0.70, 0.90)
17.70 (8.10, 27.30)
4.30 (1.95, 6.65)
0.04 (0.02, 0.06)
3.00 (-0.33, 6.33)
1.90 (-3.00, 6.80)
100.00
%
17.82
1.54
1.54
10.47
6.26
7.41
5.33
0.86
Weight
3.95
0.65
1.08
18.22
0.25
3.44
18.35
1.89
0.92
-27.3 0 27.3
NOTE: Weights are from random effects analysis
Fig. 1. Prevalence of schizophrenia in epilepsy (1.3%).
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odds of having schizophrenia.73 There was strong evidence of clustering of the asso-
ciation between epilepsy and psychosis within families. Individuals with a parental
history of epilepsy had a 2-fold increase in the odds of developing a psychotic disorder
compared with patients without a parental history of epilepsy. Reciprocally, individ-
uals with a parental history of psychotic disorder had a 2.8-fold increase in the
odds of having a diagnosis of generalized epilepsy compared with individuals without
a parental history of psychosis.
This evidence suggests that epilepsy and psychotic illness may represent different
outcomes of a common etiologic process. Neuropathologic, neuroimaging, and
genetics findings show that similar structural brain abnormalities and genetic abnormal-
ities are present in patients with schizophrenia and patients with epilepsy.74–77 For
instance, enlarged ventricles have been found common to first-episode psychosis
and temporal lobe epilepsy patients without psychosis.78 Neuronal migration defects
have been proposed as a mechanism related to enlarged ventricles and this defect
could be common to schizophrenia and epilepsy. From a neurobiological perspective,
significant gray matter and white matter deficits occur in temporal lobe epilepsy with
psychosis. Some of these deficits overlap with those found in schizophrenia. These
include themedial temporal structures but also extend to lateral temporal and extratem-
poral regions.79 Recent genetic work shows that a rare genetic mutation can lead to
either epilepsy or schizophrenia. Amicrodeletion in the genomic area 15q13-14 contain-
ing the nicotine receptor was linked to development of either schizophrenia or juvenile
epilepsy.77
In summary, a history of epilepsy in patients increases their risk of developing
schizophrenia. An improved understanding of the mechanism underlying this
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etiopathogenesis of both psychosis and epilepsy.ACQUIRED BRAIN INJURY AS A RISK FACTOR FOR SCHIZOPHRENIA
Acquired brain injury (ABI) increases the risk of psychiatric illness80–82 but the question
of whether ABI is a risk factor for schizophrenia remains controversial. Earlier studies
stated that there was a 2-fold to 3-fold increased risk of psychosis after an ABI.83 More
recent studies have contradicted this view and reported that there is limited evidence
between an association between head injury and psychosis.83–85 Consensus is
divided and this can often lead to difficulties from a medicolegal viewpoint.
We conducted a recent systematic review and meta-analysis on population-based
controlled studies and showed a significant association between traumatic brain injury
and schizophrenia with an OR of 1.65 (95% CI, 1.17–2.32). It is difficult, however, to
definitively establish causality. Patients who develop psychosis after head injury
may already have been at risk of psychosis before the injury. Confounders include
illicit substance use. In patients with a family history of psychosis, the contribution
of head injury may be greater to susceptible patients. Two family studies yielded
a pooled OR of 2.8 (95% CI, 1.17–2.32). The impact of head injuries seems to be
greater among those with an inherited susceptibility to schizophrenia.86,87 Studies
have also found an increased rate of pre-existing psychosis among people with
head injury and it is thought that psychosis increases the risk for ABI.88 The apparent
complexity of the causal pathway between ABI and schizophrenia adds to the diffi-
culty of investigating this relationship. Influences of gene-environment interaction or
an epigenenetic mechanism must be considered.
There does not seem to be a dose-response between the severity of the head injury
and the subsequent risk of schizophrenia. When subdivided by severity of ABI, the
pooled ORs were similar in studies providing rates for mild head injury specifically
(1.17) to estimates for severe head injury (1.18). Achte and colleagues89 followed-up
3552 Finnish soldiers who had received head injuries during World War II. During
this period, 2.6% developed psychoses resembling schizophrenia, which is much
higher than the incidence expected in the normal population. Soldiers with mild
head injuries developed schizophrenia more frequently than those with severe head
injuries. Factors independent of the injury may play a decisive role.ANTI-NMDA RECEPTOR ENCEPHALITIS AS A RISK FACTOR FOR SCHIZOPHRENIA
Anti–NMDA receptor encephalitis is a severe form of encephalitis associated with
antibodies against NR1 and NR2 subunits and occurs primarily in females. Prominent
features on initial presentation include psychotic symptoms and may be misdiag-
nosed as first-onset schizophrenia.90 There can be motor changes, such as catatonia,
seizures, and dyskinesias. There are also behavioral changes, autonomic dysfunction,
and impaired consciousness.91 The combination of psychotic symptoms with cata-
tonia and orofacial dyskinesias, which are indicators of dopaminergic involvement,
are all consistent with the effects of the NMDA receptor antagonist, phencyclidine,
which replicates many aspects of the presentation of schizophrenia.92 It is also impli-
cated in phencyclidine induced psychosis.
The psychiatric presentations of these cases of anti-NMDA receptor encephalitis
thus provide important support for the NMDA receptor hypofunction hypothesis for
psychosis and the possibility that autoantibodies to the NMDA receptor subunits
may be implicated in the development of psychosis is novel.
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Family Studies
Historically, the evidence from family studies of schizophrenia have shown that that
a sibling or child of a person with schizophrenia has a 10-fold increased risk of devel-
oping schizophrenia compared with the risk in the general population.93 The risk in
a recent large register-based study has shown lower risks (ORs 2–4) and lack of spec-
ificity for schizophrenia among offspring of parents with nonaffective psychosis.94
Adoption and cross-fostering studies show an increased risk of schizophrenia in the
biological but not the adoptive families of schizophrenic adoptees.95
Twin Studies and the Heritability Index
Twin studies have shown that the concordance rates for schizophrenia in monozygotic
(MZ) twins is approximately 40% to 50% whereas the concordance rate for dizygotic
(DZ) twins is 6% to 10%.96,97 Heritability estimates are approximately 80%, which
make schizophrenia among the most heritable of psychiatric disorders. Heritability
calculations assume, however, no interactions among genes or between gene and
the environment—an assumption that may have significant implications for the validity
of these estimations.98 Another assumption is that MZ twins share their environment to
an equal degree as DZ twins. This assumption may not be valid in particular when
considering the prenatal environment because MZ pairs differ from DZ pairs in terms
of sharing the placenta (ie, MZ twins are more likely to share a placenta). For this
reason, MZ twins may share more of the prenatal environment than DZ twins and,
as discussed in this article, prenatal life is a rich source of risk factors for later schizo-
phrenia. The risk of schizophrenia and schizophrenia-related disorders is similar for
the offspring of both affected and unaffected MZ twins,99,100 providing support for
the presence of unexpressed genotypes in schizophrenia and the importance of
epigenetics.
Genome-Wide Association Studies
Over the past 2 decades there has been a concentration of effort and resources in
investigating the molecular genetics of schizophrenia (for review, see the article by
Gejman and colleagues101). The initial approach involved candidate gene studies
and more than 1000 genes have been studied in schizophrenia (www.szgene.org)
but with little replication of findings. The newer approach has been to use genome-
wide association studies (GWAS), which interrogate the genome systematically and
are independent of a prior hypothesis (Table 2). To date, 12 GWAS studies have
been published, but, despite large sample sizes, the problem of nonreplication has
not been eliminated. The largest study, a mega-analysis with a discovery sample of
21,856 and a replication of samples of 29,839 individuals, was published in October
2011 by the Schizophrenia Psychiatric Genome-Wide Association Study Consortium
and found 5 new schizophrenia loci not previously identified in the other GWAS.102
The best-replicated finding from GWAS is evidence for involvement of the major
histocompatibility complex (MHC) locus. The MHC locus has a high gene density
but genes with an immune function predominate—which links back to the epidemio-
logic data on infections and autoimmunity as risk factors for schizophrenia (discussed
elsewhere). Another notable feature of these GWAS studies is the small effect sizes of
the genes identified. ORs are usually approximately 1.10. An elegant analysis by
the International Schizophrenia Consortium103 estimated that hundreds (perhaps
thousands) of genes may be involved in conferring risk for schizophrenia, each with
small effect. The investigators showed that an aggregate score, derived from the
Table 2
Top genes or genomic regions identified in schizophrenia GWAS and ORs
Authors and Year Sample (Case-Control) Gene or Region OR
Lencz et al,159 2007 178/144 CSF2RA, SHOX 3.23
Sullivan et al,160 2008 738/733 AGBL1 6.01
O’Donovan et al,161 2008 Discovery: 479/2937
Follow-up: 6829/9987
ZNF804A 1.12
Need et al,162 2009 Discovery: 871/863
Follow-up: 1460/12,995
ADAMTSL3 0.68
Purcell et al,163 2009 (ISC) 3322/3587 MHC 0.82
Stefansson et al,164
2009 (SGENE)
Discovery: 2663/13,498
Follow-up: 4999/15,555
MHC
NRGN
TCF4
1.16
1.15
1.23
Shi et al,165 2009 (MGS) 2681/2653
1286/973 (AA)
MHC
CENTG2
ERBB4
0.88
1.23
0.73
Ikeda et al,166 2010 575/564 OAT 0.57
Yue et al,167 2011 Discovery: 746/1599 (AA)
Follow-up: 4027/5603 (AA)
ZKSCAN4
NKAPL
PGBD1
TSPAN18
0.79
0.78
0.79
1.29
Shi et al,168 2011 Discovery: 3750/6468 (AA)
Follow-up: 4383/4539 (AA)
Rs10489202
Rs1060041
Rs11586522
Rs16887244
Rs1488935
1.12
1.11
1.04
0.83
0.871
Gejman et al,101 2011 (PGC) Discovery: 9394/12,462
Follow-up: 8442/21,397
MIR137
PCGEM1
TRIM26
CSMD1
MMP16
CNNM2
NT5C2
STT3A
CCDC68
TCF4
1.12
1.20
1.15
1.11
1.10
1.10
1.15
1.11
1.10
1.23
Abbreviations: AA, Asian ancestry; ISC, International schizophrenia consortium; MGS, molecular
genetics of schizophrenia study; PGC, schizophrenia psychiatric genome-wide association study
consortium; SGENE, A large scale genome-wide association study of schizophrenia addressing vari-
ation in expressivity and contribution from environmental factors.
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association results in a discovery sample, can predict up to 3% of the variance in
a target group. Using a different approach, Agerbo and colleagues104 came to the
same conclusion and reported that the percentage of excess risk associated with
a family history of schizophrenia mediated through genome-wide SNP variation
ranged up to a maximum of 4%. This raises the question, “Where is the missing heri-
tability?”105,106 It may be surmised that the “missing heritability” is likely to lie in the
environment or gene-environment interaction, which is not captured by individual
SNPs or their combination. The area of epigenetics is a promising area of investiga-
tion in the coming years.
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In addition to the reports of common SNP variations, many rare structural genomic
variants, such as copy number variants (CNVs), have been identified (for review, see
the article by Gejman and colleagues101). These rare variants seem to have larger
effect sizes than SNPs but many are private mutations confined to single families.
These variants are not specific to schizophrenia and confer risk for a variety of condi-
tions, such as epilepsy, autistic spectrum disorder, and attention-deficit/hyperactivity
disorder. An interesting aspect of these structural variants is that so many affect genes
are implicated in brain development, which links nicely with the neurodevelopmental
hypothesis of schizophrenia described first in the late 1980s and discussed elsewhere
in this article. Apart from their rarity, a problematic aspect of the large CNVs identified
to date is that they span multiple genes and the contribution of each gene may be diffi-
cult to disentangle. Nevertheless, some commentators hold that these rare variants
could hold the key to explaining the transmission of schizophrenia and argue
that mutations with the largest effects in individuals, regardless of their frequency
in the population, is the most informative as to the underlying pathogenesis of
schizophrenia.
Several conclusions can be drawn from the GWAS and CNV studies so far:
 Common variants for schizophrenia identified to date are of small effect.
 There is substantial overlap between the genetic architecture of schizophrenia
and bipolar disorder.
 There is a large unexplained gap between heritability estimates from family
studies and the amount of genetic variation that can be attributed to genome-
wide SNP variation.
GENE-ENVIRONMENT INTRERACTION
There are strong indications, from several sources, that gene/environment interactions
are important in the cause of schizophrenia. There is evidence from animal work that
neuregulin-1 and DISC1 may modify the consequences of prenatal immune activa-
tion107,108 and that neuregulin 1 may modify the effect of exposure to social defeat.107
There is also evidence from human studies that COMT may modify the effects of
adolescent exposure to cannabis,15 that individuals at high genetic risk for schizo-
phrenia are particularly sensitive to the adverse effects of a negative family rearing
environment,109 and the effect of urbanicity is mediated by genetic liability to
psychosis.110 The urbanicity studies found that 60% to 70% of those in the sample
who developed schizophrenia did so as a result of the synergistic action between
urban dwelling and familial liability to psychosis.
Our study of prenatal infection and family history of psychosis found that up to half
of the cases of schizophrenia in the sample could be attributed to the synergistic
action of prenatal infection exposure and familial liability to psychotic disorder. The
possibility of OCs interacting with underlying genetic vulnerability has been raised
by several other lines of evidence.111–114 In particular, recent findings show that
many of the susceptibility genes identified for schizophrenia are affected by
hypoxia.115–117 Nicodemus and colleagues116 performed a gene-environment interac-
tion analysis in a family study of schizophrenia probands, siblings, and controls. The
authors examined whether a set of schizophrenia candidate genes affected by
hypoxia or involved in vascular function in the brain interacted with serious OCs to
influence risk for schizophrenia. They found that 4 of the 13 genes examined showed
evidence for significant serious OC-by-gene interaction. All of the OCs rated as
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pregnancy, extended labor, delivery problems, and respiratory distress at birth. The 4
genes found to interact with these OCs, AKT1, BDNF, GRM3, and DTNBP1, showed
previous evidence of an association with schizophrenia and were affected by hypoxia.
In keeping with the epidemiological findings discussed previously, the OCs identified
in this study were diverse and occurred during both prenatal and perinatal periods.
The overall evidence suggests that these exogenous environmental factors are
working on a developmentally vulnerable brain in which endogenous factors have
gone awry to produce synergistic increases in risk of schizophrenia in adulthood.
PREVENTION
If gene-environment interaction is important in the etiology of schizophrenia, then pre-
venting the environmental exposures will reduce some of the risk associated with
susceptibility genes as well as reducing the risk associated with the independent
effects of the environmental exposures. It has been calculated that there is an infection
population-attributable proportion of 30% in the samples used to analyze the associ-
ations between schizophrenia and influenza, toxoplasmosis, and genital-reproductive
infections. If these 3 infections had been prevented, then there would have been 30%
fewer cases of schizophrenia in the patient groups examined in these studies. It has
also been suggested that the start of influenza immunization may have been respon-
sible for a reduction in the rate of schizophrenia beginning in the 1950s.118 Evidence
like this has been used in support of suggestions that greater coverage of the pregnant
population with wide-ranging immunization would decrease the incidence of schizo-
phrenia in the general population. McGrath and colleagues50 have calculated that
almost 44% of the schizophrenia cases in a Danish cohort may have been due to
nonoptimal neonatal vitamin D levels. McGrath and colleagues49 had previously pre-
sented evidence that vitamin D supplementation in males in Finland was associated
with a reduction in the incidence of schizophrenia in that population, indicating the
potential usefulness of supplementation at a population level for micronutritional defi-
ciencies. As noted by McGrath and Lawlor,119 however, although infection and nutri-
tion may be the exposures most amenable to public health intervention, the evidence
is not yet robust enough to justify such action.
Fig. 2 shows the multifactorial, highly complex potential causal pathways to schizo-
phrenia. It seems likely that some seemingly independent risk factors are actually
taking place at different times along the same causal pathway. If the antecedent
factors can be identified, perhaps through large cohorts with multiples exposures
measured, then where best to aim preventative strategies can be investigated. For
example, as discussed previously, there is evidence that maternal stress during preg-
nancy increases the risk of fetal hypoxia. If maternal stress during pregnancy can be
prevented or reduced, then some of the risk associated with hypoxia may be able to
be reduced.
CLINICAL PREDICTION OF PSYCHOSIS RISK: THE ULTRA–HIGH-RISK APPROACH
Psychosis is usually preceded by a prodromal period before full-blown illness. This
period is characterized by the presence of psychotic symptoms at a subthreshold
level of intensity and/or duration or frequency compared with established psychotic
disorder. Although the psychosis prodrome is, by definition, a retrospective diagnosis,
several research groups have developed criteria aimed at prospectively identifying
young people during the prodrome, before onset of first-episode psychosis. These
criteria have been formalized in several instruments, including the Comprehensive
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Fig. 2. Proposed pathways and mechanisms linking OCs and risk of schizophrenia. (Repro-
duced from Clarke MC, Roddy S, Cannon M. Obstetric complications and schizophrenia:
historical overview and new directions. In: Brown AS, Patterson PH, editors. The origins of
schizophrenia. New York: Columbia University Press; 2011. p. 96–119; with permission.)
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Syndromes.121 Three prodromal risk syndromes have been described in these instru-
ments, characterized by
1. Attenuated positive symptoms
2. Frank psychotic symptoms that are brief in duration or
3. Genetic risk combined with functional deterioration
Prospective studies have demonstrated that approximately 15% to 40% of young
people who present to the clinic with these putative prodromal risk syndromes go
on to develop a psychotic disorder within the proceeding 2 years.122–126 As a result,
these individuals are considered an ultra–high-risk (UHR) group for psychosis.127
Neurocognitive Manifestations of Psychosis Risk
A great deal of research has been conducted addressing neurocognitive risk factors
associated with prodromal risk syndromes, which helps inform about the underlying
pathophysiology associated with psychosis risk. This has included research on
working memory, attention/vigilance, executive functioning, verbal learning/memory,
and speed of processing. Research has shown impairments across most of these
cognitive domains in UHR samples.
Working memory
Verbal and spatial working memory have both been shown to be impaired in
UHR samples, using assessments, such as letter-number span tasks, delayed match-
to-sample tasks, spatial board tasks, and hidden tokens tasks. Several different groups
have demonstrated verbal and spatial working memory deficits in UHR samples.128–133
Wood and colleagues,134 for example, demonstrated spatial working memory deficits in
an Australian sample of 38 UHR patients using a block-tapping test. Smith and
colleagues135 have also shown spatial working memory deficits in an American sample
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deficits on a letter-number sequencing task in a sample of 36 Canadian and American
UHR patients, a finding recently replicated by Carrion and colleagues137 in a larger
sample of UHR patients (n 5 127) also using the letter-number sequencing task.
Attention and vigilance
The Continuous Performance Test is the classic task used in neurocognitive assess-
ments of attention and vigilance. Hambrecht and colleagues138 conducted one of the
earliest such tests in a sample of 51 putatively prodromal patients and found that the
UHR sample demonstrated significantly poorer scores compared with healthy
controls. Attention deficits have now been demonstrated many times across different
studies.131–134
Executive function
Tasks, such as the Wisconsin Card Sorting Test (WCST) and the Tower of Hanoi, are
among the most commonly used measures of executive functioning in UHR samples.
Several groups have demonstrated executive function deficits in UHR patients.130–132
Pukrop and colleagues139 showed deficits on the WCST in a German sample of 90
UHR patients. Pflueger and colleagues,129 using both the WCST and Tower of Hanoi
tasks, also found executive functioning deficits in a sample of 60 UHR patients in
Basel, Switzerland. Most recently, in one of the largest studies to date, Carrion and
colleagues137 showed deficits on the WCST in a sample of 127 UHR patients.
Verbal learning/memory
Several different tasks are used to assess verbal learning and memory, which include
assessing the participants’ ability to immediately recall words as well as their ability to
recall the words after a delay. The California Verbal Learning Test, Hopkins Verbal
Learning Test, and the Rey Auditory Verbal Learning Test are frequently used, with
immediate and delayed testing trials, as well as the Wechsler Memory Scale. Verbal
learning tasks regularly show some of the greatest levels of impairment relative to
other neurocognitive domains.137–142 Niendam and colleagues,142 for example,
showed pronounced verbal learning deficits in a sample of 45 12-year-old to 29-
year-old UHR patients attending a prodromal clinic in California. Similarly, Jhashan
and colleagues143,144 demonstrated marked deficits in verbal learning in a sample
of 48 12-year-old to 30-year-old patients with prodromal syndromes.
Processing speed
Tests of processing speed have been used less frequently than tests of other neuro-
cognitive domains but have consistently demonstrated, in studies incorporating them,
some of the most marked neurocognitive impairments. Processing speed tasks used
have included the Trail Making Test, digit symbol-coding test, the Stroop Color and
Word Test, and verbal fluency tests.130 Hawkins and colleagues136 found deficits in
a sample of 36 American and Canadian UHR patients using a digit symbol-coding
task and the Stroop Color and Word Test. Eastvold and colleagues130 reported that
a sample of 40 UHR patients performed significantly more poorly on the Stroop Color
and Word Test compared with healthy controls. Simon and colleagues140 reported
poorer scores in a sample of 69 UHR patients on both the Trail Making Test and verbal
fluency tests. Frommann and colleagues132 found, in a sample of German patients
who were in the early versus late stages of the prodrome, that although patients in
the later stage of the prodrome demonstrated a range of neurocognitive deficits,
early-stage prodromal patients uniquely showed processing speed deficits. The
authors have recently conducted one of the first studies of prodromal syndromes
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patients, up to 8% fulfilled criteria for a prodromal risk syndrome. Using the Measure-
ment and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)
consensus neurocognitive battery, young people who met criteria for prodromal risk
syndromes demonstrated deficits in processing speed, including on the Trail Making
Test, Part A, and the symbol-coding task from the Brief Assessment of Cognition in
Schizophrenia, as well as deficits in nonverbal working memory, using the Wechsler
Memory Scale spatial span task.146 Deficits were most pronounced on the symbol-
coding task from the Brief Assessment of Cognition in Schizophrenia (z score differ-
ence between UHR group and controls 5 1), in line with the findings of Frommann
and colleagues132 that processing speed deficits are the main finding in the early
UHR stages.
In the largest study to date of neurocognitive functioning in patients with prodromal
syndromes, Seidman and colleagues133 found that processing speed, measured with
a symbol-coding task, was the most pronounced of all neurocognitive deficits. Most
recently, Carrion and colleagues137 have also shown in a large sample of American
UHR patients that not only were processing speed deficits especially pronounced
relative to most other neurocognitive deficits but also processing speed deficits
were uniquely predictive of social and role functioning, independent of positive
psychotic symptoms. This is interesting given that some researchers have suggested
that symbol-coding deficits reflect the core of schizophrenia neurocognitive impair-
ment.147,148 In a meta-analysis of 40 studies, Dickinson148 reported that the effect
size of the impairment on a symbol-coding task significantly exceeded the effect sizes
of tasks commonly used to measure more specific cognitive domains, including
episodic memory, executive function, and working memory. This, they have argued,
represents a systems-based dysfunction, which may be at the heart of psychosis
risk, reflecting a process of disturbed integration and coordination between distrib-
uted brain networks.
The Community Approach
Although UHR research has been in progress in the clinic, a parallel stream of research
has been ongoing in the general population, studying psychosis from a broader
perspective, that is, individuals in the community who experience isolated psychotic
symptoms. These symptoms are especially prevalent in young people, with meta-
analyses demonstrating a median population prevalence of 17% among children
ages 9 years to 12 years and 7.5% among adolescents ages 13 years to 18 years.149
By comparison, a meta-analysis of (mainly) adult studies demonstrated a population
prevalence of 5% for psychotic symptoms.150 The presence of these symptoms at
a subclinical level in the community is of clinical interest because, as in UHR studies,
longitudinal research has demonstrated that these symptoms are associated with
increased risk for psychotic disorder in adulthood, albeit not to the same degree as
in UHR patients. In an influential article, Poulton and colleagues151 demonstrated
that community-based children who reported psychotic symptoms at age 11 were,
at age 26, at a 5-fold to 16-fold increased risk of schizophreniform disorder. This finding
was replicated by researchers in an Australian sample, who showed that self-reported
auditory hallucinations at age 14 years were associated with increased risk for
psychotic disorder at age 21.152 Young people in the general population who report
psychotic symptoms have been shown to share a wide range of risk factors with
schizophrenia patients, including social, environmental, substance use, obstetric,
developmental, anatomic, and intellectual risk factors.153 For these reasons, this pop-
ulation has been considered to form part of an extended psychosis phenotype,
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psychotic symptoms on one end and schizophrenia patients on the other end.
Researchers have argued that work on this extended psychosis phenotype may
provide valuable insights into the etiology of clinical psychotic disorder.154,155 Neuro-
cognitive research has only recently begun on this population but some of the cognitive
differences that are characteristic of the prodrome and first-episode psychosis have
already been shown to also occur in this population. In particular, deficits in processing
speed have been found pronounced in this group. Blanchard and colleagues,156 for
example, showed that, in addition to poorer scores in tests of receptive language
and motor skills, young people with psychotic symptoms performed more poorly on
the Trail Making Test, Part B. This is in line with a previous cohort study, which de-
monstrated that childhood performance on this task predicted schizophrenia in
adulthood.157 Using the MATRICS battery in a sample of more than 200 community-
based adolescents, we have recently shown that psychotic symptoms are associated
with significantly poorer scores in tests of processing speed andworkingmemory, with
performance on digit symbol-coding particularly pronounced.158 This mirrors findings
in UHR sample as well as in first-episode psychosis.
SUMMARY
There is strong evidence for involvement of a range of environmental risk factors in the
pathway to schizophrenia. These include OCs, prenatal infection, prenatal stress,
prenatal nutrition, and adolescent cannabis use. These risk factors, however, are
neither necessary nor sufficient causal factors for schizophrenia. The majority of
people who are exposed to them do not develop schizophrenia and a majority of indi-
viduals with schizophrenia may not have had the specific exposure in question. These
risk factors are component causes embedded in highly complex pathways to schizo-
phrenia in which some of these risk factors may add to, mediate, or moderate each
other’s effects. Just as with genetic risk factors, however, a risk factor should not
be ignored because it is of small effect. It is likely that these environmental risk factors
also affect the outcome of genetic risk factors for schizophrenia through gene/environ-
ment interaction and/or through epigenetic effects. In addition, work studying the
etiologic overlap between neurodevelopmental disorders, such as epilepsy and
schizophrenia, and work on the extended psychosis phenotype are starting to provide
potentially valuable insights into the etiology of clinical psychotic disorder.
REFERENCES
1. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia:
historical and meta-analytic review. Am J Psychiatry 2002;159:1080–92.
2. Byrne M, Agerbo E, Bennedsen B, et al. Obstetric conditions and risk of
first admission with schizophrenia: a Danish national register based study.
Schizophr Res 2007;97:51–9.
3. Gunnell D, Rasmussen F, Fouskakis D, et al. Patterns of fetal and childhood
growth and the development of psychosis in young males: a cohort study. Am
J Epidemiol 2003;158:291–300.
4. Gunnell D, Harrison G, Whitley E, et al. The association of fetal and childhood
growth with risk of schizophrenia. Cohort study of 720,000 Swedish men and
women. Schizophr Res 2005;79:315–22.
5. Sørensen HJ, Mortensen EL, Reinisch JM, et al. Do hypertension and diuretic
treatment in pregnancy increase the risk of schizophrenia in offspring? Am J
Psychiatry 2003;160:464–8.
Clarke et al6046. Sørensen HJ, Mortensen EL, Reinisch JM, et al. Association between prenatal
exposure to analgesics and risk of schizophrenia. Br J Psychiatry 2004;160:
366–71.
7. Insel BJ, Brown AS, Bresnahan MA, et al. Maternal-fetal blood incompatibility
and the risk of schizophrenia in offspring. Schizophr Res 2005;80:331–42.
8. Boog G. Obstetrical complications and further schizophrenia of the infant: a new
methodological threat to the obstetrician? J Gynecol Obstet Biol Reprod 2003;
32:720–7.
9. Boksa P, El-Khodor BF. Birth insult interacts with stress at adulthood to alter
dopaminergic function in animal models: possible implications for schizo-
phrenia and other disorders. Neurosci Biobehav Rev 2003;27:91–101.
10. Cannon TD, Yolken R, Buka S, et al. Collaborative study group on the perinatal
origins of severe psychiatric D. Decreased neurotrophic response to birth
hypoxia in the etiology of schizophrenia. Biol Psychiatry 2008;64:797–802.
11. Dalman C. Obstetric complications and risk of schizophrenia: an association
appears undisputed, yet mechanisms are still unknown. Lakartidningen 2003;
100:1974–9.
12. Cannon TD, Rosso IM, Hollister JM, et al. A prospective cohort study of Genetic
and perinatal influences in the etiology of schizophrenia. Schizophr Bull 2000;
26:249–56.
13. Casadio P, Di Forti M, Murray RM. Cannabis use as a component cause of
schizophrenia. In: Brown AS, Patterson PH, editors. The origins of schizo-
phrenia. Columbia University Press; 2011. p. 157–75.
14. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of
psychosis. Br J Psychiatry 2009;195(6):488–91.
15. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-
onset cannabis use on adult psychosis by a functional polymorphism in the
catechol-O-methyltransferase gene: longitudinal evidence of a gene X environ-
ment interaction. Biol Psychiatry 2005;57(10):1117–27.
16. Henquet C, Rosa A, Delespaul P, et al. COMT ValMet moderation of cannabis-
induced psychosis: a momentary assessment study of ‘switching on’ hallucina-
tions in the flow of daily life. New York: Columbia University Press; Acta Psychiatr
Scand 2009;119(2):156–60.
17. Henquet C, Murray R, Linszen D, et al. The environment and schizophrenia: the
role of cannabis use. Schizophr Bull 2005;31(3):608–12.
18. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of
psychotic or affective mental health outcomes: a systematic review. Lancet
2007;370(9584):319–28.
19. Mednick SA, Machon RA, Huttunen MO, et al. Adult schizophrenia following
prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988;45:
189–92.
20. Brown AS. Maternal infection and schizophrenia. In: Brown AS, Patterson PH,
editors. The origins of schizophrenia. New York: Columbia University Press;
2011. p. 25–57.
21. Brown AS, Cohen P, Greenwald S, et al. Nonaffective psychosis after prenatal
exposure to rubella. Am J Psychiatry 2000;157:438–43.
22. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal
influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004;61:
774–80.
23. Cannon M, Kendell R, Susser E, et al. Prenatal and perinatal risk factors for
schizophrenia. In: Murray RM, Jones PB, Susser E, et al, editors. The
Predicting Risk and the Emergence of Schizophrenia 605epidemiology of schizophrenia. Cambridge (UK): Cambridge University Press
Cambridge University Press; 2002. p. 74–99.
24. Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia.
Schizophr Bull 2006;32:3–8.
25. Brown AS, Cohen P, Harkavy-Friedman J, et al. Prenatal rubella, premorbid
abnormalities, and adult schizophrenia. Biol Psychiatry 2001;49(6):473–86.
26. Clarke MC, Tanskanen A, Huttunen M, et al. Evidence for an Interaction between
familial liability and prenatal exposure to infection in the causation of schizo-
phrenia. Am J Psychiatry 2009;166(9):1025–30.
27. Gilmore JH, Jarskog LF. Exposure to infection and brain development:
cytokines in the pathogenesis of schizophrenia. Schizophr Res 1997;24(3):
365–7.
28. Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders:
evidence and therapeutic implications. Drugs 2005;65(11):1493–520.
29. Arion D, Unger T, Lewis DA, et al. Molecular evidence for increased expression
of genes related to immune and chaperone function in the prefrontal cortex in
schizophrenia. Biol Psychiatry 2007;62(7):711–21.
30. Patterson PH. Anmial models of the maternal infection risk factor. In: Brown AS,
Patterson PH, editors. The origins of schizophrenia. Columbia University Press;
2011. p. 255–81.
31. Huttunen MO, Niskanen P. Prenatal loss of father and psychiatric disorders.
Arch Gen Psychiatry 1978;35(4):429–31.
32. Khashan AS, Abel KM, McNamee R, et al. Higher risk of offspring schizophrenia
following antenatal maternal exposure to severe adverse life events. Arch Gen
Psychiatry 2008;65(2):146–52.
33. van Os J, Selten JP. Prenatal exposure to maternal stress and subsequent
schizophrenia. The May 1940 invasion of The Netherlands. Br J Psychiatry
1998;172:324–6.
34. Imamura Y, Nakane Y, Ohta Y, et al. Lifetime prevalence of schizophrenia among
individuals prenatally exposed to atomic bomb radiation in Nagasaki City. Acta
Psychiatr Scand 1999;100(5):344–9.
35. Malaspina D, Corcoran C, Kleinhaus KR, et al. Acute maternal stress in preg-
nancy and schizophrenia in offspring: a cohort prospective study. BMC Psychi-
atry 2008;8:71.
36. Myhrman A, Rantakallio P, Isohanni M, et al. Unwantedness of a pregnancy and
schizophrenia in the child. Br J Psychiatry 1996;169(5):637–71.
37. Koenig JI, Kirkpatrick B, Lee P. Glucocorticoid hormones and early
brain development in schizophrenia. Neuropsychopharmacology 2002;27(2):
309–18.
38. Patterson PH. Anmial models of the maternal stress risk factor. In: Brown AS,
Patterson PH, editors. The origins of schizophrenia. New York: Columbia Univer-
sity Press; 2011. p. 335–64.
39. Iampietro MC, Ellman LM. Maternal stress during pregnancy and schizophrenia.
In: Brown AS, Patterson PH, editors. The origins of schizophrenia. Columbia
University Press; 2011. p. 120–39.
40. Sharma S, Norris WE, Kalkunte S. Beyond the threshold: an etiological bridge
between hypoxia and immunity in preeclampsia. J Reprod Immunol 2010;
85(1):112–6.
41. Epel E, Lapidus R, McEwen B, et al. Stress may add bite to appetite in women:
a laboratory study of stress-induced cortisol and eating behavior. Psychoneur-
oendocrinology 2001;26(1):37–49.
Clarke et al60642. Read J, van Os J, Morrison AP, et al. Childhood trauma, psychosis and schizo-
phrenia: a literature review with theoretical and clinical implications. Acta
Psychiatr Scand 2005;112:330–50.
43. Morgan C, Fisher H. Environmental factors in schizophrenia: childhood
trauma—a critical review. Schizophr Bull 2007;33:3–10.
44. Harley M, Kelleher I, Clarke M, et al. Cannabis use and childhood trauma
interact additively to increase the risk of psychotic symptoms in adolescence.
Psychol Med 2010;40(10):1627–34.
45. Kelleher I, Harley M, Lynch F, et al. Associations between childhood trauma,
bullying and psychotic symptoms among a school-based adolescent sample.
Br J Psychiatry 2008;193:378–82.
46. Heins M, Simons C, Lataster T, et al. Childhood trauma and psychosis: a case-
control and case-sibling comparison across different levels of genetic liability,
psychopathology, and type of trauma. Am J Psychiatry 2011;168(12):1286–94.
47. Cougnard A, Marcelis M, Myin-Germeys I, et al. Does normal developmental
expression of psychosis combine with environmental risk to cause persistence
of psychosis? A psychosis proneness-persistence model. Psychol Med 2007;
37:513–27.
48. Brown AS, Bottiglieri T, Schaefer CA, et al. Elevated prenatal homocysteine
levels as a risk factor for schizophrenia. Arch Gen Psychiatry 2007;64(1):31–9.
49. McGrath J, Saari K, Hakko H, et al. Vitamin D supplementation during the first
year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr
Res 2004;67(2–3):237–45.
50. McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin D status and risk of
schizophrenia: a population-based case-control study. Arch Gen Psychiatry
2010;67(9):889–94.
51. Insel BJ, Schaefer CA, McKeague IW, et al. Maternal iron deficiency and the risk
of schizophrenia in offspring. Arch Gen Psychiatry 2008;65(10):1136–44.
52. Cui X, Eyles DW, Burne TH, et al. Developmental Vitamin D deficiency as a risk
factor for schizophrenia. In: Brown AS, Patterson PH, editors. The origins of
schizophrenia. New York: Columbia University Press; 2011. p. 282–99.
53. Tarantino LM, Reyes TM, Palmer AA. Animal models of prenatal protein malnu-
trition relevant for schizophrenia. In: Brown AS, Patterson PH, editors. The
origins of schizophrenia. Columbia University Press; 2011. p. 300–34.
54. Harper KN, Brown AS. Prenatal nutrition and the etiology of schizophrenia. In:
Brown AS, Patterson PH, editors. The origins of schizophrenia. New York:
Columbia University Press; 2011. p. 58–95.
55. Hollister JM, Laing P, Mednick SA. Rhesus incompatibility as a risk factor for
schizophrenia in male adults. Arch Gen Psychiatry 1996;53:19–24.
56. Brown AS, Schaefer CA, Quesenberry CP Jr, et al. Maternal exposure to toxo-
plasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 2005;
162(4):767–73.
57. Brown AS, Schaefer CA, Quesenberry CP Jr, et al. No evidence of relation
between maternal exposure to herpes simplex virus type 2 and risk of schizo-
phrenia? Am J Psychiatry 2006;163(12):2178–80.
58. Brown AS, Schaefer CA, Wyatt RJ, et al. Maternal exposure to respiratory infec-
tions and adult schizophrenia spectrum disorders: a prospective birth cohort
study. Schizophr Bull 2000;26(2):287–95.
59. Babulas V, Factor-Litvak P, Goetz R, et al. Prenatal exposure to maternal genital
and reproductive infections and adult schizophrenia. Am J Psychiatry 2006;
163(5):927–9.
Predicting Risk and the Emergence of Schizophrenia 60760. Sørensen HJ, Nielsen PR, Pedersen CB, et al. Association between prepartum
maternal iron deficiency and offspring risk of schizophrenia: population-based
cohort study with linkage of Danish national registers. Schizophr Bull 2011;
37(5):982–7.
61. McGrath J, Eyles D, Mowry B, et al. Low maternal vitamin D as a risk factor for
schizophrenia: a pilot study using banked sera. Schizophr Res 2003;63(1–2):73–8.
62. Esquirol E. Des maladies mentales considerees sous les rapports medical. JB
Balliere; 1838.
63. Kraeplin E. Psychiatrie: Ein Lehrbuch fur Studierende und Artze. Leipzig
(Germany): Barth; 1913.
64. Flor-Henry P. Psychosis and temporal lobe epilepsy. A controlled investigation.
Epilepsia 1969;10(3):363–95.
65. Trimble MR. The psychoses of epilepsy. New York: Raven Press; 1991.
66. Gibbs EL, Gibbs FA, Fuster B. Psychomotor epilepsy. Arch Neurol Psychiatry
1948;60(4):331–9.
67. Slater E, Beard AW, Glithero E. The schizophrenialike psychoses of epilepsy. Br
J Psychiatry 1963;109:95–150.
68. Schmitz B. Psychosis in epilepsy: frequency and risk factors. J Epilepsy 1995;8:
295–305.
69. Swinkels WA, Kuyk J, van Dyck R, et al. Psychiatric comorbidity in epilepsy.
Epilepsy Behav 2005;7(1):37–50.
70. Jensen I, Larsen JK. Mental aspects of temporal lobe epilepsy. Follow-up of 74
patients after resection of a temporal lobe. J Neurol Neurosurg Psychiatry 1979;
42(3):256–65.
71. Gudmundsson G. Epilepsy in Iceland. A clinical and epidemiological investiga-
tion. Acta Neurol Scand 1966;43(Suppl 25):1–124.
72. Qin P, Xu H, Laursen TM, et al. Risk for schizophrenia and schizophrenia-like
psychosis among patients with epilepsy: population based cohort study. BMJ
2005;331(7507):23.
73. Clarke M, Tanskanen A, Huttunen MO, et al. Evidence for shared genetic
susceptibility to epilepsy and psychosis: a population based family study. Biol
Psychiatry 2012;71(9):836–9.
74. Bruton CJ, Stevens JR, Frith CD. Epilepsy, psychosis, and schizophrenia:
clinical and neuropathologic correlations. Neurology 1994;44(1):34–42.
75. Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 Microdeletions increase risk of
idiopathic generalized epilepsy. Nat Genet 2009;41(2):160–2.
76. Masurel-Paulet A, Andrieux J, Callier P, et al. Delineation of 15q13.3 microdele-
tions. Clin Genet 2010;78(2):149–61.
77. Vassos E, Collier DA, Holden S, et al. Penetrance for copy number variants
associated with schizophrenia. Hum Mol Genet 2010;19(17):3477–81.
78. Barr WB, Ashtari M, Bilder RM, et al. Brain morphometric comparison of first-
episode schizophrenia and temporal lobe epilepsy. Br J Psychiatry 1997;170:
515–9.
79. Sundram F, Cannon M, Doherty CP, et al. Neuroanatomical correlates of
psychosis in temporal lobe epilepsy: voxel-based morphometry study. Br J
Psychiatry 2010;197(6):482–92.
80. Bryant RA, O’Donnell ML, Creamer M, et al. The psychiatric consequences of
traumatic brain injury. Am J Psychiatry 2010;167:312–20.
81. Fleminger S. Head injury. In: David A, Fleminger S, Kopelman MD, et al, editors.
Lishman’s organic psychiatry: a textbook of neuropsychiatry. 4th edition. Black-
well Publishing; 2009. p. 167–279.
Clarke et al60882. Davidson K, Bagley CR. Schizophrenia-like psychosis associated with organic
disorders of the central nervous system: a review of the literature. Current prob-
lems of neuropsychiatry. Br J Psychiatry 1969;(Special publication 4):S113–84.
83. David A, Prince M. Psychosis following head injury: a critical review. J Neurol
Neurosurg Psychiatry 2005;76(Suppl 1):i53–60.
84. Kim E. Does traumatic brain injury predispose individuals to develop schizo-
phrenia? Curr Opin Psychiatry 2009;21:286–9.
85. Hesdorffer DC, Rauch SL, Tamminga CA. Long-term psychiatric outcomes
following traumatic brain injury: a review of the literature. J Head Trauma Rehabil
2009;24:452–9.
86. Malaspina D, Goertz RR, Friedman JH, et al. Traumatic brain injury and schizo-
phrenia in members of schizoiphrenia and bipolar pedigrees. Am J Psychiatry
2001;158:440–6.
87. Nielsen AS, Mortensen PB, O’Callaghan E, et al. Is head injury a risk factor for
schizophrenia? Schizophr Res 2002;55:93–8.
88. Fann JR, Burington MS, Leonetti A, et al. Psychiatric illness following traumatic
brain injury in an adult health maintenance organisation population. Arch Gen
Psychiatry 2004;61:53–61.
89. Achte KA, Hillbom E, Aalberg V. Psychoses following war brain injuries. Acta
Psychiatr Scand 1969;225:1–94.
90. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA receptor encephalitis: case
series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–8.
91. Barry H, Hardiman O, Healy DG, et al. Anti-NMDA receptor encephalitis: an
important differential diagnosis in psychosis. Br J Psychiatry 2011;199:508–9.
92. Baldridge EB, Bessen HA. Phencyclidine. Emerg Med Clin Morth Am 1990;8:
541–50.
93. Gottesman II, Shields J. Schizophrenia: the epigenetic puzzle. Cambridge
(United Kingdom): Cambridge University Press; 1982.
94. Dean K, Stevens H, Mortensen PR, et al. Full spectrum of psychiatric outcomes
among offspring with parental history of mental disorder. Arch Gen Psychiatry
2010;67:822–9.
95. Ingraham LJ, Kety SS. Adoption studies of schizophrenia. Am J Hum Genet
2000;97:18–22.
96. Cardno AG, Gottesman I. Twin studies of schizophrenia: from bow-and-arrow
concordances to Star Wars Mx and functional genomics. Am J Med Genet
2000;97:12–7.
97. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence
from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187–92.
98. Schwartz S, Susser E. Twin studies of heritability. In: Susser E, Schwzrtz S,
Morabia A, et al, editors. Psychiatric epidemiology. New York: Oxford University
Press; 2006.
99. Kringlen E, Cramer G. Offspring of monozygotic twins discordant for schizo-
phrenia. Arch Gen Psychiatry 1989;46:873–7.
100. Gottesman II, Bertelsen A. Confirming unexpressed genotypes for schizo-
phrenia: risks in the offspring of Fischer’s Danish identical and fraternal discor-
dant twins. Arch Gen Psychiatry 1989;46:867–72.
101. Gejman PV, Sanders AR, Kendler KS. Genetics of schizophrenia: new findings
and challenges. Annu Rev Genomics Hum Genet 2011;12:121–44.
102. PGC (Schizophrenia Psychiatric Genome-Wide Association Study Consortium).
Genome-wide association study identifies five new schizophrenia loci. Nat
Genet 2011;43(10):969–76.
Predicting Risk and the Emergence of Schizophrenia 609103. ISC (International Schizophrenia Consortium). Common polygenic variation
contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:
748–52.
104. Agerbo E, Mortensen PB, Wiuf C, et al. Modelling the contribution of family
history and variation in singly nucleotide polymorphisms to risk of schizo-
phrenia: a Danish national birth cohort-based study. Schizophr Res 2012;
134:246–52.
105. Maher B. Personal genomes: the case of the missing heritability. Nature 2008;
456:18–21.
106. Mitchell KJ, Porteous DJ. Rethinking the genetic architecture of schizophrenia.
Psychol Med 2011;41:19–32.
107. O’Tuathaigh CM, Harte M, O’Leary C, et al. Schizophrenia-related endopheno-
types in heterozygous neuregulin-1 ‘knockout’ mice. Eur J Neurosci 2010;
31(2):349–58.
108. Ibi D, Nagai T, Koike H, et al. Combined effect of neonatal immune activation
and mutant DISC1 on phenotypic changes in adulthood. Behav Brain Res
2010;206(1):32–7.
109. Tienari P, Wynne LC, Sorri A, et al. Genotype-environment interaction in
schizophrenia-spectrum disorder. Long-term follow-up study of Finnish adoptees.
Br J Psychiatry 2004;184:216–22.
110. van Os J, Pedersen CB, Mortensen PB. Confirmation of synergy between urban-
icity and familial liability in the causation of psychosis. Am J Psychiatry 2004;
161:2312–4.
111. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;19:2063–72.
112. Devlin B, Klei L, Myles-Worsely M, et al. Genetic liability to schizophrenia
Oceanic Palau: a search in the affected and maternal generation. Hum Genet
2007;121:675–84.
113. Mittal VA, Ellman LM, Cannon TD. Gene-environment interaction and co varia-
tion in schizophrenia: the role of obstetric complications. Schizophr Bull 2008;
34:1083–94.
114. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia,
revisited. Schizophr Bull 2009;35:528–48.
115. Schmidt-Kastner R, van Os J, Steinbusch H, et al. Gene regulation by hypoxia
and the neurodevelopmental origin of schizophrenia. Schizophr Res 2006;
84(2–3):253–71.
116. Nicodemus KK, Marenci S, Batten AJ, et al. Serious obstetric complications
interact with hypoxia-regulated vascular expression genes to influence schizo-
phrenia risk. Mol Psychiatry 2008;18:180–4.
117. Clarke MC, Roddy S, Cannon M. Obstetric complications and schizophrenia:
Historical overview and new directions. In: Brown AS, Patterson PH, editors. The
origins of schizophrenia. New York: Columbia University Press; 2011. p. 96–119.
118. Suvisaari JM, Haukka JK, Tanskanen AJ, et al. Decline in the incidence of
schizophrenia in Finnish cohorts born from 1954 to 1965. Arch Gen Psychiatry
1999;56(8):733–40.
119. McGrath JJ, Lawlor DA. The search for modifiable risk factors for schizophrenia.
Am J Psychiatry 2011;168(12):1235–8.
120. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young
people at incipient risk of psychosis. Schizophr Bull 1996;22(2):283–303.
121. McGlashan TH, Miller TJ, Woods SW. Pre-onset detection and intervention
research in schizophrenia psychoses: current estimates of benefit and risk.
Schizophr Bull 2001;27(4):563–70.
Clarke et al610122. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk
syndrome for first psychosis: findings from the North American Prodrome Longi-
tudinal Study. Schizophr Bull 2009;35(5):894–908.
123. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at
high clinical risk: a multisite longitudinal study in North America. Arch Gen
Psychiatry 2008;65(1):28–37.
124. Nelson B, Yung AR. Can clinicians predict psychosis in an ultra high risk group?
Aust N Z Psychiatry 2010;44(7):625–30.
125. Ziermans TB, Schothorst PF, Sprong M, et al. Transition and remission in adoles-
cents at ultra-high risk for psychosis. Schizophr Res 2011;126(1–3):58–64.
126. Addington J, Cadenhead KS, Cannon TD, et al. North American Prodrome
Longitudinal Study: a collaborative multisite approach to prodromal schizo-
phrenia research. Schizophr Bull 2007;33(3):665–72.
127. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of
a high-risk (“prodromal”) group. Schizophr Res 2003;60(1):21–32.
128. Gschwandtner U, Pfluger M, Aston J, et al. Fine motor function and neuropsy-
chological deficits in individuals at risk for schizophrenia. Eur Arch Psychiatry
Clin Neurosci 2006;256(4):201–6.
129. Pflueger MO, Gschwandtner U, Stieglitz RD, et al. Neuropsychological deficits
in individuals with an at risk mental state for psychosis—working memory as
a potential trait marker. Schizophr Res 2007;97(1–3):14–24.
130. Eastvold AD, Heaton RK, Cadenhead KS. Neurocognitive deficits in the (putative)
prodrome and first episode of psychosis. Schizophr Res 2007;93(1–3):266–77.
131. Kim KR, Park JY, Song DH, et al. Neurocognitive performance in subjects at
ultrahigh risk for schizophrenia: a comparison with first-episode schizophrenia.
Compr Psychiatry 2011;52(1):33–40.
132. Frommann I, Pukrop R, Brinkmeyer J, et al. Neuropsychological profiles in
different at-risk states of psychosis: executive control impairment in the
early—and additional memory dysfunction in the late—prodromal state. Schiz-
ophr Bull 2011;37(4):861–73.
133. Seidman LJ, Giuliano AJ, Meyer EC, et al. Neuropsychology of the prodrome to
psychosis in the NAPLS consortium: relationship to family history and conver-
sion to psychosis. Arch Gen Psychiatry 2010;67(6):578–88.
134. Wood SJ, Pantelis C, Proffitt T, et al. Spatial working memory ability is a marker
of risk-for-psychosis. Psychol Med 2003;33(7):1239–47.
135. Smith CW, Park S, Cornblatt B. Spatial working memory deficits in adolescents
at clinical high risk for schizophrenia. Schizophr Res 2006;81(2–3):211–5.
136. Hawkins KA, Addington J, Keefe RS, et al. Neuropsychological status of
subjects at high risk for a first episode of psychosis. Schizophr Res 2004;
67(2–3):115–22.
137. Carrion RE, Goldberg TE, McLaughlin D, et al. Impact of neurocognition on
social and role functioning in individuals at clinical high risk for psychosis. Am
J Psychiatry 2011;168(8):806–13.
138. Hambrecht M, Lammertink M, Klosterkotter J, et al. Subjective and objective
neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychi-
atry Suppl 2002;43:s30–7.
139. Pukrop R, Schultze-Lutter F, Ruhrmann S, et al. Neurocognitive functioning in
subjects at risk for a first episode of psychosis compared with first- and
multiple-episode schizophrenia. J Clin Exp Neuropsychol 2006;28(8):1388–407.
140. Simon AE, Cattapan-Ludewig K, Zmilacher S, et al. Cognitive functioning in the
schizophrenia prodrome. Schizophr Bull 2007;33(3):761–71.
Predicting Risk and the Emergence of Schizophrenia 611141. Lencz T, Smith CW, McLaughlin D, et al. Generalized and specific neurocogni-
tive deficits in prodromal schizophrenia. Biol Psychiatry 2006;59(9):863–71.
142. Niendam TA, Bearden CE, Johnson JK, et al. Neurocognitive performance and
functional disability in the psychosis prodrome. Schizophr Res 2006;84(1):100–11.
143. Jahshan C, Heaton RK, Golshan S, et al. Course of neurocognitive deficits in the
prodrome and first episode of schizophrenia. Neuropsychology 2010;24(1):
109–20.
144. Keefe RS, Perkins DO, Gu H, et al. A longitudinal study of neurocognitive func-
tion in individuals at-risk for psychosis. Schizophr Res 2006;88(1–3):26–35.
145. Kelleher I, Murtagh A, Molloy C, et al. Identification and characterization of
prodromal risk syndromes in young adolescents in the community: a popula-
tion-based clinical interview study. Schizophr Bull 2012;38(2):239–46.
146. Kelleher I, Murtagh A, Murphy J, et al. Neurocognition in a community sample of
young people at putative ultra high risk for psychosis assessed using the
MATRICS consensus neurocognitive battery: processing speed as the core
deficit. Cogn Neuropsychiatry, in Press.
147. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic
comparison of digit symbol coding tasks and other cognitive measures in
schizophrenia. Arch Gen Psychiatry 2007;64(5):532–42.
148. Dickinson D. Digit symbol coding and general cognitive ability in schizophrenia:
worth another look? Br J Psychiatry 2008;193(5):354–6.
149. Kelleher I, Connor D, Clarke MC, et al. Prevalence of psychotic symptoms
in childhood and adolescence: a systematic review and meta-analysis of
population-based studies. Psychol Med 2012. [Epub ahead of print].
150. van Os J, Linscott RJ, Myin-Germeys I, et al. A systematic review and meta-analysis
of the psychosis continuum: evidence for a psychosis proneness-persistence-
impairment model of psychotic disorder. Psychol Med 2009;39(2):179–95.
151. Poulton R, Caspi A, Moffitt TE, et al. Children’s self-reported psychotic symp-
toms and adult schizophreniform disorder: a 15-year longitudinal study. Arch
Gen Psychiatry 2000;57(11):1053–8.
152. Welham J, Scott J, Williams G, et al. Emotional and behavioural antecedents of
young adults who screen positive for non-affective psychosis: a 21-year birth
cohort study. Psychol Med 2009;39(4):625–34.
153. Kelleher I, Cannon M. Psychotic-like experiences in the general population:
characterizing a high-risk group for psychosis. Psychol Med 2011;41(1):1–6.
154. Polanczyk G, Moffitt TE, Arseneault L, et al. Etiological and clinical features of
childhood psychotic symptoms: results from a birth cohort. Arch Gen Psychiatry
2010;67(4):328–38.
155. Laurens KR, Hodgins S, Maughan B, et al. Community screening for psychotic-
like experiences and other putative antecedents of schizophrenia in children
aged 9-12 years. Schizophr Res 2007;90(1–3):130–46.
156. Blanchard MM, Jacobson S, Clarke MC, et al. Language, motor and speed of
processing deficits in adolescents with subclinical psychotic symptoms. Schiz-
ophr Res 2010;123(1):71–6.
157. Cannon M, Moffitt TE, Caspi A, et al. Neuropsychological performance at the
age of 13 years and adult schizophreniform disorder: prospective birth cohort
study. Br J Psychiatry 2006;189:463–4.
158. Kelleher I, Clarke MC, Rawdon C, et al. Neurocognition in the extended
psychosis phenotype: performance of a community sample of adolescents
with psychotic symptoms on the MATRICS neurocognitive battery. Schizophr
Bull, in press.
Clarke et al612159. Lencz T, Lambert C, DeRosse P, et al. Runs of homozygosity reveal highly pene-
trant recessive loci in schizophrenia. Proc Natl Acad Sci 2007;104(50):19942–7.
160. Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in
the CATIE study: results of stage 1. Mol Psychiatry 2008;13(6):570–84.
161. O’Donovan MC, Craddock N, Norton N, et al. Identification of loci associated
with schizophrenia by genome-wide association and follow-up. Nat Genet
2008;40(9):1053–5.
162. Need AC, Goldstein DB. Whole genome association studies in complex
diseases: where do we stand? Dialogues Clin Neurosci 2010;12(1):37–46.
163. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to
risk of schizophrenia and bipolar disorder. Nature 2009;460(7256):748–52.
164. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of
schizophrenia. Nature 2009;460(7256):744–7.
165. Shi J, Levinson DF, Duan J. Common variants on chromosome 6p22.1 are asso-
ciated with schizophrenia. Nature 2009;460(7256):753–7.
166. Ikeda M, Aleksic B, Kirov G, et al. Copy number variation in schizophrenia in the
Japanese population. Biol Psychiatry 2010;67(3):283–6.
167. Yue WH, Wang HF, Sun LD, et al. Genome-wide association study identifies
a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet
2011;43(12):1228–31.
168. Shi Y, Li Z, Xu Q, et al. Common variants on 8p12 and 1q24.2 confer risk of
schizophrenia. Nat Genet 2011;43(12):1224–7.
